These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11821003)

  • 1. [Positron emission tomography (PET) in oncology (Part I)].
    Gámez Cenzano C; Cabrera Villegas A; Sopena Monforte R; García Velloso MJ
    Rev Esp Med Nucl; 2002 Feb; 21(1):41-60; quiz 61-3. PubMed ID: 11821003
    [No Abstract]   [Full Text] [Related]  

  • 2. ¹¹C-acetate PET/CT imaging: physiologic uptake, variants, and pitfalls.
    Karanikas G; Beheshti M
    PET Clin; 2014 Jul; 9(3):339-44. PubMed ID: 25030397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Cancer Metabolism with Positron Emission Tomography (PET).
    Witney TH; Lewis DY
    Methods Mol Biol; 2019; 1928():29-44. PubMed ID: 30725448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of metabolic PET imaging in radiation oncology.
    Zhu A; Marcus DM; Shu HK; Shim H
    Radiat Res; 2012 Apr; 177(4):436-48. PubMed ID: 22339451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells].
    Minosako Y; Nemoto M; Ino S; Shirakami Y; Kurami M
    Kaku Igaku; 2003 Feb; 40(1):23-30. PubMed ID: 12701204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Positron emission tomography/computed tomography with 18F-FDG. PET Working Group. Procedures Committee of the Spanish Society of Nuclear Medicine].
    García Garzón JR; Rodríguez A; Cabrera A
    Rev Esp Med Nucl; 2009; 28(2):85-9. PubMed ID: 19406058
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation for performing ¹¹C-methionine and ¹⁸F-FDG-PET studies on the same day.
    Mitsumoto T; Kubota K; Sato T; Morooka M; Minamimoto R; Shimbo T; Muramatsu Y; Sasaki T; Ito K; Fukushi M
    Nucl Med Commun; 2012 Mar; 33(3):297-304. PubMed ID: 22107999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic imaging of a malignant myxofibrosarcoma with F-18-FDG and C-11-methionine positron emission tomography].
    Weckesser E; Redeker J; Kühnel G; Börner AR; Flügel M; Knapp WH
    Nuklearmedizin; 2000; 39(3):N38-9. PubMed ID: 10834199
    [No Abstract]   [Full Text] [Related]  

  • 9. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation.
    Smith TA
    Nucl Med Biol; 2001 Jan; 28(1):1-4. PubMed ID: 11182558
    [No Abstract]   [Full Text] [Related]  

  • 10. Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.
    Herrmann K; Buck AK
    PET Clin; 2014 Jul; 9(3):331-8. PubMed ID: 25030396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls.
    Beheshti M; Haroon A; Bomanji JB; Langsteger W
    PET Clin; 2014 Jul; 9(3):299-306. PubMed ID: 25030393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.
    Sanz-Viedma S; Torigian DA; Parsons M; Basu S; Alavi A
    Rev Esp Med Nucl; 2009; 28(3):159-66. PubMed ID: 19558958
    [No Abstract]   [Full Text] [Related]  

  • 13. Positron emission tomography in oncology.
    Leskinen-Kallio S
    Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations.
    Gordon BA; Flanagan FL; Dehdashti F
    AJR Am J Roentgenol; 1997 Dec; 169(6):1675-80. PubMed ID: 9393189
    [No Abstract]   [Full Text] [Related]  

  • 15. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer.
    McDougall IR; Davidson J; Segall GM
    Nucl Med Commun; 2001 May; 22(5):485-92. PubMed ID: 11388568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Potential use of positron-emission tomography in clinical oncology].
    Fukuda H; Matsuzawa T; Tateno Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):860-5. PubMed ID: 3291774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer diagnosis with positron emission tomography (PET)].
    Kubota K
    Kaku Igaku; 1996 Feb; 33(2):207-12. PubMed ID: 8721109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
    Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
    J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring response to treatment in the development of anticancer drugs using PET.
    Price P
    Nucl Med Biol; 2000 Oct; 27(7):691. PubMed ID: 11091114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.